AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.
AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.
AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.
AHA 2017 A restrictive RBC transfusion strategy with 7.5 g/dL as trigger was non-inferior to a strategy with 9.5 g/dL for mortality and major morbidity in patients undergoing cardiac surgery in TRICS III.
AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.
AHA 2017 BRUISE CONTROL 2 was a blinded randomized trial that compared periprocedural continuation or interruption of DOAC therapy and found similarly low rates of CVA/TIA and hematoma.
Stepwise higher concentrations of nonfasting triglycerides were associated with a stepwise higher risk of heart failure, which was not the case for LDL-c.
Patients with SHTG treated with OM3-CA 2 g daily had a statistically significant reduction in TG and non-HDL-c concentrations compared with those treated with olive oil 2 g daily.
In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, the role of diabetes treatment in the management of heart failure, as well as novel interventions targeted to improve CV outcomes were discussed.
Lessons learned from the EMPA-REG OUTCOME trial: prof Anker suggested that empagliflozin may prevent the development of HF. However, he emphasized that new trials are needed to test the effect of SGLT2 inhibitors in the treatment of HF in diabetes patients.
A summary of the beneficial effects of the SGLT2 inhibitor empagliflozin and GLP-1 receptor agonist liraglutide on CV outcome in patients with diabetes and CVD was given by prof. Deanfield. He raised the point that this is a new era for CVD management in diabetes patients and discussed current and future studies.
In a large retrospective cohort study, the risk of dementia was higher without oral anticoagulant treatment in patients with AF, compared with AF patients receiving oral anticoagulation.